Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

India’s first domestically produced HPV vaccine by SII to improve affordability for those most at need, says GlobalData

Serum Institute of India’s (SII) Cervavac—a quadrivalent human papillomavirus (qHPV) vaccine— is likely to be the first indigenous qHPV vaccine to be approved in India, according to GlobalData. The leading data and analytics company notes that this will not only make the drug more affordable to Indians, but it will significantly improve the overall penetration […]
Read more

CStone sugemalimumab to face stiff competition in NSCLC segment in China, says GlobalData

The National Medical Products Administration (NMPA) of China has recently approved CStone Pharmaceuticals’ sugemalimumab (Cejemly) to treat patients with stage III non-small cell lung cancer (NSCLC), whose disease has not progressed following concurrent or sequential or platinum-based chemoradiotherapy. Against this backdrop, sugemalimumab will still face stiff competition in China, observes GlobalData, a leading data and […]
Read more

Biological E. has carved out its place in India’s COVID-19 vaccine market following Corbevax’s approval, says GlobalData

The Drugs Controller General of India (DCGI) recently approved Biological E.’s Corbevax vaccine as the first heterogeneous COVID-19 booster vaccine in India for adults above 18 years who have received two shots of Covaxin or Covishield. Corbevax has the added advantage of scalability and thermostability, making it suitable for deployment in low-resource settings, says GlobalData. […]
Read more

Digital campaigns hoped to boost breast cancer awareness in India as country to see third-highest rise in cases worldwide, says GlobalData

Out of 16 markets worldwide*, India saw the third-highest rise in total HER2+ breast cancer cases, according to GlobalData. The leading data and analytics company notes that the country is expected to see total incident cases increase from 255,749 in 2022 to 311,128 by 2030 at an annual growth rate (AGR) of 2.84%. GlobalData highlights […]
Read more

Oxurion NV’s THR-149 has potential to address key unmet need in the ophthalmology market, says GlobalData

Preclinical research for Oxurion NV’s THR-687 was presented at the Association for Research in Ophthalmology (ARVO) last month, forecasting its promising potential within the DME space. However, Oxurion NV recently announced it would no longer pursue its Phase IIb INTEGRAL for THR-687 for the treatment of diabetic macular edema (DME), stating its decision to progress […]
Read more

WatchOS 9’s long-anticipated key workout and health features will continue to ensure Apple’s domination of the wearables market, says GlobalData

Following the announcement of WatchOS 9 during Apple’s 2022 WWDC event; Ardit Ballhysa, Technology Analyst at GlobalData, a leading data and analytics company, offers his view: “This year’s WatchOS update focuses heavily on staying ‘active and healthy’, two elements that are paramount to the success of a wearable device. “WatchOS 9 builds on the Workout […]
Read more

Smart pacifiers in development will be helpful for infants in the NICU as they reduce the need for bloodwork, says GlobalData

Following the news that researchers from Washington State University have developed a smart pacifier to monitor newborn infants; Alexandra Murdoch, Medical Device Analyst at GlobalData, a leading data and analytics company offers her view: “This device will be especially helpful for babies who are in the neonatal intensive care unit (NICU), as they are at […]
Read more

MVA-BN respiratory syncytial virus vaccine could get first-to-market opportunity in China, says GlobalData

Bavarian Nordic has recently announced an exclusive license and supply agreement with China’s Nuance Pharma to develop and commercialize their candidate MVA-BN respiratory syncytial virus (RSV) vaccine in adults in China Mainland, Hong Kong, Macau, Taiwan, South Korea, and Southeast Asian countries. Leveraging Nuance Pharma’s local presence could provide a unique first-to-market opportunity for MVA-BN […]
Read more

Borrena (lorlatinib) approval further strengthens Pfizer position in China NSCLC market, says GlobalData

The National Medical Products Administration (NMPA) of China has recently approved Pfizer’s third generation ALK inhibitor Borrena (lorlatinib) as the first-line treatment for adults with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Pfizer already has deep commercial experience in China’s NSCLC market, and this approval will further strengthen its position within the […]
Read more

Alpha-1 Antitrypsin Deficiency market to reach $3.48 billion in 2031 driven by entrance of several novel therapies, says GlobalData

An upcoming influx of new therapies into the Alpha-1 Antitrypsin Deficiency (AATD) space in the next decade is expected to provide a significant boost to the treatment market for this inherited disorder that can greatly damage both lung and liver function, found GlobalData. According to the leading data and analytics company, the two major markets* […]
Read more

UCB is well-positioned to become a key player in the myasthenia gravis market with zilucoplan and rozanolixizumab, says GlobalData

Positive Phase III trial results from UCB’s two clinical trials in its generalized myasthenia gravis (gMG) program will enable it to become a key future player in the MG market, with both zilucoplan and rozanolixizumab expected to enter the market next year, says GlobalData, a leading data and analytics company. Philippa Salter, Neurology Analyst at […]
Read more

Top 20 global biopharmaceutical companies by market capitalization (quarter ended March 31, 2022), presented by GlobalData

The top 20 global biopharmaceutical companies by market capitalization (MCAP) experienced a favorable Q1 2022, despite global economic and financial market uncertainty. The majority of the top 20 global biopharmaceutical companies reported a 2.1% increase in aggregate MCAP, from $3.4 trillion on 31 December 2021 to $3.5 trillion as of 31 March 2022, according to […]
Read more

Complement inhibition is becoming a key neuroimmunology mechanism of action, with pipeline agents spanning numerous indications, says GlobalData

The complement cascade, an arm of the innate immune system consisting of a collection of small proteins with various functions in targeting pathogens, has been implicated in the pathology of a number of different neurological diseases, from autoimmune diseases like myasthenia gravis (MG) to neurodegenerative diseases like amyotrophic lateral sclerosis (ALS), says GlobalData. The leading […]
Read more

Osteoarthritis pipeline shifting from analgesics to disease-modifying treatments as conventional analgesics offer inadequate pain relief, says GlobalData

The current osteoarthritis (OA) market has previously suffered from a lack of effective analgesics and disease-modifying osteoarthritis drugs (DMOADs) partially due to the complex pathophysiology of OA and the lack of appropriate outcome measures for progression of joint damage, says GlobalData. However, the leading data and analytics company notes that drugs that are currently under […]
Read more
1 … 47 48 49 50 51 … 110